BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214. [PMID: 21208101 DOI: 10.1056/nejmoa1011418] [Cited by in Crossref: 590] [Cited by in F6Publishing: 250] [Article Influence: 59.0] [Reference Citation Analysis]
Number Citing Articles
1 Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H, Sun M, Chai Z, Hou P, Geng X, Liu W, Wei M. Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy. Oncol Lett 2018;16:5621-30. [PMID: 30344717 DOI: 10.3892/ol.2018.9398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
3 Friend S, Royce M. The Changing Landscape of Breast Cancer: How Biology Drives Therapy. Medicines (Basel) 2016;3:E2. [PMID: 28930112 DOI: 10.3390/medicines3010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
4 Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol 2013;3:301. [PMID: 24392349 DOI: 10.3389/fonc.2013.00301] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
5 Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7:308-322. [PMID: 23148997 DOI: 10.1016/j.molonc.2012.10.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
6 Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016;10:893-905. [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
7 Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018;24:701-16. [PMID: 28913723 DOI: 10.1007/s12253-017-0307-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kern KM, Schroeder JR. Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics. Int J Breast Cancer 2014;2014:423059. [PMID: 25302124 DOI: 10.1155/2014/423059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
9 Hodge DQ, Cui J, Gamble MJ, Guo W. Histone Variant MacroH2A1 Plays an Isoform-Specific Role in Suppressing Epithelial-Mesenchymal Transition. Sci Rep 2018;8:841. [PMID: 29339820 DOI: 10.1038/s41598-018-19364-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797-3803. [PMID: 21965336 DOI: 10.1172/jci57152] [Cited by in Crossref: 232] [Cited by in F6Publishing: 129] [Article Influence: 23.2] [Reference Citation Analysis]
11 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29:807-19. [PMID: 22692561 DOI: 10.1007/s10585-012-9496-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
12 Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther 2015;16:678-83. [PMID: 25928118 DOI: 10.1080/15384047.2015.1026481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
13 Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy PJ. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res 2011;13:R133. [PMID: 22192147 DOI: 10.1186/bcr3079] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
14 Jekimovs C, Bolderson E, Suraweera A, Adams M, O'Byrne KJ, Richard DJ. Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. Front Oncol 2014;4:86. [PMID: 24795863 DOI: 10.3389/fonc.2014.00086] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
15 Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H, Baar J. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol. 2013;44:2159-2166. [PMID: 23845471 DOI: 10.1016/j.humpath.2013.04.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
16 Bahamin N, Ahmadian S, Rafieian-Kopaei M, Mobini G, Shafiezadeh M, Soltani A. A Comparative Study on Anticancer Effects of the Alhagi maurorum and Amygdalus haussknechtii Extracts Alone and in Combination with Docetaxel on 4T1 Breast Cancer Cells. Evid Based Complement Alternat Med 2021;2021:5517944. [PMID: 34221071 DOI: 10.1155/2021/5517944] [Reference Citation Analysis]
17 Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 2011;13:218. [PMID: 21884642 DOI: 10.1186/bcr2877] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
18 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
19 Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19:664-78. [PMID: 21575865 DOI: 10.1016/j.ccr.2011.04.010] [Cited by in Crossref: 297] [Cited by in F6Publishing: 272] [Article Influence: 29.7] [Reference Citation Analysis]
20 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
21 Walsh EM, Keane MM, Wink DA, Callagy G, Glynn SA. Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. Crit Rev Oncog 2016;21:333-51. [PMID: 29431082 DOI: 10.1615/CritRevOncog.2017021307] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
22 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
23 Makhale A, Nanayakkara D, Raninga P, Khanna KK, Kalimutho M. CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer. Int J Mol Sci 2021;22:5782. [PMID: 34071360 DOI: 10.3390/ijms22115782] [Reference Citation Analysis]
24 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 198] [Article Influence: 33.4] [Reference Citation Analysis]
25 Liu Y, Xu H, Van der Jeught K, Li Y, Liu S, Zhang L, Fang Y, Zhang X, Radovich M, Schneider BP, He X, Huang C, Zhang C, Wan J, Ji G, Lu X. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 2018;128:2951-65. [PMID: 29649003 DOI: 10.1172/JCI98727] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
26 Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7. [PMID: 21316599 DOI: 10.1016/j.ccr.2011.01.047] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
27 Kandula M, Ch KK, Ys AR. Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. World J Oncol 2013;4:137-41. [PMID: 29147345 DOI: 10.4021/wjon681e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
28 George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 2019;125:2732-46. [PMID: 31017664 DOI: 10.1002/cncr.32150] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Patterson MJ, Sutton RE, Forrest I, Sharrock R, Lane M, Kaufmann A, O'Donnell R, Edmondson RJ, Wilson BT, Curtin NJ. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br J Cancer 2014;111:94-100. [PMID: 24867690 DOI: 10.1038/bjc.2014.261] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
30 Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011;99:331-8. [PMID: 21719137 DOI: 10.1016/j.radonc.2011.05.084] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
31 Garay JP, Gray JW. Omics and therapy - a basis for precision medicine. Mol Oncol 2012;6:128-39. [PMID: 22445068 DOI: 10.1016/j.molonc.2012.02.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
32 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
33 Sajesh BV, Guppy BJ, McManus KJ. Synthetic genetic targeting of genome instability in cancer. Cancers (Basel) 2013;5:739-61. [PMID: 24202319 DOI: 10.3390/cancers5030739] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
34 Sharma M, Turaga RC, Yuan Y, Satyanarayana G, Mishra F, Bian Z, Liu W, Sun L, Yang J, Liu ZR. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. J Exp Med 2021;218:e20200712. [PMID: 33561195 DOI: 10.1084/jem.20200712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yin ZX, Hang W, Liu G, Wang YS, Shen XF, Sun QH, Li DD, Jian YP, Zhang YH, Quan CS, Zeng Q, Li YL, Zhao RX, Ding Q, Xu ZX. PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation. Oncotarget 2018;9:1885-97. [PMID: 29416738 DOI: 10.18632/oncotarget.21277] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
36 Zeichner SB, Terawaki H, Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2016;10:25-36. [PMID: 27042088 DOI: 10.4137/BCBCR.S32783] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
37 Sun DE, Ye SY. Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment. Cancer Manag Res 2020;12:6103-12. [PMID: 32765105 DOI: 10.2147/CMAR.S253042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res 2018;30:315-26. [PMID: 30046226 DOI: 10.21147/j.issn.1000-9604.2018.03.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
39 Breuer EK, Murph MM. The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities. Int J Proteomics 2011;2011:373584. [PMID: 21886869 DOI: 10.1155/2011/373584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
40 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012;134:649-59. [PMID: 22678161 DOI: 10.1007/s10549-012-2106-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
41 Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res 2012;72:2802-13. [PMID: 22491672 DOI: 10.1158/0008-5472.CAN-11-3152] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
42 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
43 Shibata H, Miuma S, Saldivar JC, Huebner K. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. Cancer Sci 2011;102:1882-8. [PMID: 21707865 DOI: 10.1111/j.1349-7006.2011.02016.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
44 O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015;3:257-75. [PMID: 26676166 DOI: 10.1016/j.bbacli.2015.03.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 30.7] [Reference Citation Analysis]
45 Wang L, Wang M, Zhou B, Zhou F, Murray C, Towner RA, Smith N, Saunders D, Xie G, Chen WR. PEGylated reduced-graphene oxide hybridized with Fe3O4 nanoparticles for cancer photothermal-immunotherapy. J Mater Chem B 2019;7:7406-14. [PMID: 31710067 DOI: 10.1039/c9tb00630c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
46 Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011;105:1114-22. [PMID: 21989215 DOI: 10.1038/bjc.2011.382] [Cited by in Crossref: 168] [Cited by in F6Publishing: 150] [Article Influence: 16.8] [Reference Citation Analysis]
47 Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, Fujii T, Seki N, Kawahara A, Kage M, Matsueda S, Akagi Y, Yamada A, Itoh K, Sasada T. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res 2014;16:R70. [PMID: 24992895 DOI: 10.1186/bcr3685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
48 Huang C, Han Z, Wu D. Effects of TPX2 gene on radiotherapy sensitization in breast cancer stem cells. Oncol Lett 2017;14:1531-5. [PMID: 28789376 DOI: 10.3892/ol.2017.6277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 214] [Article Influence: 32.4] [Reference Citation Analysis]
50 Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51. [PMID: 22371451 DOI: 10.1158/1078-0432.CCR-11-2425] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 12.9] [Reference Citation Analysis]
51 Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 2014;7:866-70. [PMID: 24527094 DOI: 10.3892/ol.2014.1782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
52 Yang KS, Kohler RH, Landon M, Giedt R, Weissleder R. Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci Rep 2015;5:10129. [PMID: 25984718 DOI: 10.1038/srep10129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
53 Park SH, Chung YM, Ma J, Yang Q, Berek JS, Hu MC. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget 2016;7:42110-25. [PMID: 27283899 DOI: 10.18632/oncotarget.9881] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
54 Pistollato F, Bernasconi C, McCarthy J, Campia I, Desaintes C, Wittwehr C, Deceuninck P, Whelan M. Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research. Animals (Basel) 2020;10:E1194. [PMID: 32674379 DOI: 10.3390/ani10071194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
55 Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist 2012;17:1014-26. [PMID: 22843553 DOI: 10.1634/theoncologist.2012-0043] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
56 Zhang T, Prasad P, Cai P, He C, Shan D, Rauth AM, Wu XY. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. Acta Pharmacol Sin 2017;38:835-47. [PMID: 28216624 DOI: 10.1038/aps.2016.166] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
57 Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012;19:3907-21. [PMID: 22788767 DOI: 10.2174/092986712802002464] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 8.7] [Reference Citation Analysis]
58 Wang J, Yang X, Han H, Wang L, Bao W, Wang S, Hoffman RM, Yang M, Qi H, An C, Hu K. Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models. Chin J Cancer Res 2018;30:112-21. [PMID: 29545725 DOI: 10.21147/j.issn.1000-9604.2018.01.12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
59 Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011;13:566-79. [PMID: 21636705 DOI: 10.1093/neuonc/nor039] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 10.3] [Reference Citation Analysis]
60 He ZY, Wu SG, Peng F, Zhang Q, Luo Y, Chen M, Bao Y. Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT. Transl Oncol 2017;10:1-9. [PMID: 27888707 DOI: 10.1016/j.tranon.2016.10.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
61 Shen X, Lei J, Du L. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC. Exp Ther Med 2020;19:375-83. [PMID: 31853314 DOI: 10.3892/etm.2019.8191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
62 Radovich M, Clare SE, Atale R, Pardo I, Hancock BA, Solzak JP, Kassem N, Mathieson T, Storniolo AM, Rufenbarger C, Lillemoe HA, Blosser RJ, Choi MR, Sauder CA, Doxey D, Henry JE, Hilligoss EE, Sakarya O, Hyland FC, Hickenbotham M, Zhu J, Glasscock J, Badve S, Ivan M, Liu Y, Sledge GW, Schneider BP. Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. Breast Cancer Res Treat 2014;143:57-68. [PMID: 24292813 DOI: 10.1007/s10549-013-2780-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
63 Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol 2018;36:884-90. [PMID: 29373071 DOI: 10.1200/JCO.2016.71.3495] [Cited by in Crossref: 161] [Cited by in F6Publishing: 86] [Article Influence: 53.7] [Reference Citation Analysis]
64 Martínez-Montiel N, Anaya-Ruiz M, Pérez-Santos M, Martínez-Contreras RD. Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes (Basel) 2017;8:E217. [PMID: 28981467 DOI: 10.3390/genes8100217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
65 Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:3307-29. [PMID: 25185096 DOI: 10.1200/JCO.2014.56.7479] [Cited by in Crossref: 147] [Cited by in F6Publishing: 74] [Article Influence: 21.0] [Reference Citation Analysis]
66 Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, Reyal F, Savignoni A, Asselain B, Sastre-Garau X, Almouzni G. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Mol Oncol 2015;9:657-74. [PMID: 25497280 DOI: 10.1016/j.molonc.2014.11.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
67 Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 2013;19:6163-72. [PMID: 24016618 DOI: 10.1158/1078-0432.CCR-12-3826] [Cited by in Crossref: 101] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
68 Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 2013;15:R77. [PMID: 24008095 DOI: 10.1186/bcr3471] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
69 Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011;29:373-4. [PMID: 21552220 DOI: 10.1038/nbt0511-373] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 7.8] [Reference Citation Analysis]
70 Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW, Liu RS. STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer. Theranostics 2017;7:647-63. [PMID: 28255357 DOI: 10.7150/thno.16827] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
71 Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, von Minckwitz G, Loibl S. Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) 2011;6:265-72. [PMID: 22135624 DOI: 10.1159/000331696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
72 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
73 Soung YH, Kashyap T, Nguyen T, Yadav G, Chang H, Landesman Y, Chung J. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3. Oncotarget 2017;8:52935-47. [PMID: 28881784 DOI: 10.18632/oncotarget.17987] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
74 Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 2011;129:607-16. [PMID: 21597921 DOI: 10.1007/s10549-011-1564-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
75 Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new? Future Oncol 2014;10:1215-37. [PMID: 24947262 DOI: 10.2217/fon.14.60] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 17.3] [Reference Citation Analysis]
76 Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer 2014;110:1413-9. [PMID: 24569467 DOI: 10.1038/bjc.2014.81] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
77 Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, Tseng LM, Chen WS, Shyr YM. Molecular characteristics of recurrent triple-negative breast cancer. Mol Med Rep 2015;12:7326-34. [PMID: 26458489 DOI: 10.3892/mmr.2015.4360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
78 Liu Y, Sun B, Liu T, Zhao X, Wang X, Li Y, Meng J, Gu Q, Liu F, Dong X, Liu P, Sun R, Zhao N. Function of AURKA protein kinase in the formation of vasculogenic mimicry in triple-negative breast cancer stem cells. Onco Targets Ther 2016;9:3473-84. [PMID: 27366084 DOI: 10.2147/OTT.S93015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
79 Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev 2014;23:594-600. [PMID: 24515272 DOI: 10.1158/1055-9965.EPI-13-1180] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
80 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
81 Choi YE, Pan Y, Park E, Konstantinopoulos P, De S, D'Andrea A, Chowdhury D. MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife 2014;3:e02445. [PMID: 24843000 DOI: 10.7554/eLife.02445] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.9] [Reference Citation Analysis]
82 Cazzaniga M, Bonanni B. Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012;2012:985620. [PMID: 22851887 DOI: 10.1155/2012/985620] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
83 Andreopoulou E, Sparano JA. Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. Curr Breast Cancer Rep 2013;5:42-50. [PMID: 23440080 DOI: 10.1007/s12609-012-0097-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
84 Ullal AV, Reiner T, Yang KS, Gorbatov R, Min C, Issadore D, Lee H, Weissleder R. Nanoparticle-mediated measurement of target-drug binding in cancer cells. ACS Nano 2011;5:9216-24. [PMID: 21962084 DOI: 10.1021/nn203450p] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
85 Padayachee J, Singh M. Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials. Nanobiomedicine (Rij) 2020;7:1849543520983196. [PMID: 33488814 DOI: 10.1177/1849543520983196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Pala EE, Bayol U, Keskin EU, Ozguzer A, Kucuk U, Ozer O, Koc A. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population. Pathol Oncol Res 2015;21:1223-7. [PMID: 26060045 DOI: 10.1007/s12253-015-9956-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Laimito KR, Gámez-Pozo A, Sepúlveda J, Manso L, López-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E. Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases. Ecancermedicalscience 2016;10:632. [PMID: 27170832 DOI: 10.3332/ecancer.2016.632] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
88 Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192-1199. [PMID: 21487248 DOI: 10.4161/cc.10.8.15273] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]
89 Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11:203-222. [PMID: 24569448 DOI: 10.1038/nrclinonc.2014.25] [Cited by in Crossref: 147] [Cited by in F6Publishing: 118] [Article Influence: 21.0] [Reference Citation Analysis]
90 Hirai T, Shirai H, Fujimori H, Okayasu R, Sasai K, Masutani M. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation. Cancer Sci. 2012;103:1045-1050. [PMID: 22404155 DOI: 10.1111/j.1349-7006.2012.02268.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
91 Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol 2013;33:845-57. [PMID: 23230272 DOI: 10.1128/MCB.00990-12] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
92 Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res. 2012;18:6400-6406. [PMID: 23071261 DOI: 10.1158/1078-0432.CCR-11-3150] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
93 Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer 2012;15:197-202. [PMID: 22807937 DOI: 10.4048/jbc.2012.15.2.197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
94 Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 2015;150:569-79. [PMID: 25833211 DOI: 10.1007/s10549-015-3359-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
95 Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
96 Cristofanilli M. Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. J Oncol 2012;2012:703858. [PMID: 22645612 DOI: 10.1155/2012/703858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
97 Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Cancer Med 2019;8:383-99. [PMID: 30525293 DOI: 10.1002/cam4.1892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
98 Guo J, Lv J, Chang S, Chen Z, Lu W, Xu C, Liu M, Pang X. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget 2016;7:45249-62. [PMID: 27303922 DOI: 10.18632/oncotarget.9932] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
99 Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, Boulares AH, Pacher P. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774-88. [PMID: 21884784 DOI: 10.1016/j.freeradbiomed.2011.08.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
100 Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat 2014;146:557-66. [PMID: 25001612 DOI: 10.1007/s10549-014-3039-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
101 Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18:1655-1662. [PMID: 22291137 DOI: 10.1158/1078-0432.ccr-11-2890] [Cited by in Crossref: 159] [Cited by in F6Publishing: 76] [Article Influence: 17.7] [Reference Citation Analysis]
102 Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neurooncol 2015;125:123-31. [PMID: 26285766 DOI: 10.1007/s11060-015-1876-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
103 Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 2012;118:5283-92. [PMID: 22517119 DOI: 10.1002/cncr.27568] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
104 Wu N, Zhang J, Zhao J, Mu K, Zhang J, Jin Z, Yu J, Liu J. Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer. Oncol Lett 2018;16:4984-96. [PMID: 30250564 DOI: 10.3892/ol.2018.9290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
105 Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011;6:638-49. [PMID: 21593597 DOI: 10.4161/epi.6.5.15667] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
106 Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015;16:575. [PMID: 26673577 DOI: 10.1186/s13063-015-1101-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
107 Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016;14:267. [PMID: 27634150 DOI: 10.1186/s12967-016-1027-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
108 Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012;4:515-27. [PMID: 22416035 DOI: 10.1002/emmm.201200229] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
109 Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013;19:5505-12. [PMID: 23965901 DOI: 10.1158/1078-0432.CCR-12-3327] [Cited by in Crossref: 367] [Cited by in F6Publishing: 198] [Article Influence: 45.9] [Reference Citation Analysis]
110 Carey LA, Sharpless NE. PARP and cancer--if it's broke, don't fix it. N Engl J Med 2011;364:277-9. [PMID: 21208102 DOI: 10.1056/NEJMe1012546] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
111 van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011;2:984-96. [PMID: 22184287 DOI: 10.18632/oncotarget.362] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
112 Schaue D, Mcbride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015;12:527-40. [DOI: 10.1038/nrclinonc.2015.120] [Cited by in Crossref: 174] [Cited by in F6Publishing: 154] [Article Influence: 29.0] [Reference Citation Analysis]
113 Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat 2015;154:351-7. [PMID: 26536871 DOI: 10.1007/s10549-015-3616-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
114 Chen Y, Zhang Y. Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. Adv Sci (Weinh) 2018;5:1700964. [PMID: 29938175 DOI: 10.1002/advs.201700964] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
115 Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L, Nilsson F, Paterson K, Schwabe U, Selke G, Sermet C, Simoens S, Tomek D, Vlahovic-Palcevski V, Voncina L, Wladysiuk M, van Woerkom M, Wong-Rieger D, Zara C, Ali R, Gustafsson LL. Personalizing health care: feasibility and future implications. BMC Med 2013;11:179. [PMID: 23941275 DOI: 10.1186/1741-7015-11-179] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
116 Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium. Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res 2019;25:73-9. [PMID: 30131387 DOI: 10.1158/1078-0432.CCR-18-0110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
117 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
118 Zhang D, Wang HB, Brinkman KL, Han SX, Xu B. Strategies for targeting the DNA damage response for cancer therapeutics. Chin J Cancer 2012;31:359-63. [PMID: 22704491 DOI: 10.5732/cjc.012.10087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
119 Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Oncotarget 2016;7:80363-72. [PMID: 27385001 DOI: 10.18632/oncotarget.10345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2012;9:208-214. [PMID: 22143142 DOI: 10.1038/nrclinonc.2011.190] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
121 McQuade RM, Stojanovska V, Stavely R, Timpani C, Petersen AC, Abalo R, Bornstein JC, Rybalka E, Nurgali K. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol 2018;175:656-77. [PMID: 29194564 DOI: 10.1111/bph.14114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
122 Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014;3:1579-94. [PMID: 25124282 DOI: 10.1002/cam4.317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
123 Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307-17. [PMID: 21455239 DOI: 10.1038/nrd3410] [Cited by in Crossref: 1012] [Cited by in F6Publishing: 846] [Article Influence: 101.2] [Reference Citation Analysis]
124 La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011;8:587-596. [PMID: 21862978 DOI: 10.1038/nrclinonc.2011.121] [Cited by in Crossref: 194] [Cited by in F6Publishing: 151] [Article Influence: 19.4] [Reference Citation Analysis]
125 Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013;14:537-45. [PMID: 23760496 DOI: 10.4161/cbt.24349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
126 Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013;19:977-84. [PMID: 23269547 DOI: 10.1158/1078-0432.CCR-12-0163] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
127 Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 2012;30:2684-90. [PMID: 22689801 DOI: 10.1200/JCO.2011.36.4752] [Cited by in Crossref: 68] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
128 Wang M, Zhang J, Huang Y, Ji S, Shao G, Feng S, Chen D, Zhao K, Wang Z, Wu A. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells. Med Sci Monit 2017;23:3904-12. [PMID: 28802099 DOI: 10.12659/msm.902870] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
129 Yang K, Zeng L, Ge A, Bao T, Xu T, Xie X, Liu L. Exploring the Regulation Mechanism of Xihuang Pill, Olibanum and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology. Front Pharmacol 2020;11:825. [PMID: 32595497 DOI: 10.3389/fphar.2020.00825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
130 Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res 2015;21:2722-9. [PMID: 25779953 DOI: 10.1158/1078-0432.CCR-14-2780] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
131 Gogineni K, DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res 2012;14:205. [PMID: 22429313 DOI: 10.1186/bcr3064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
132 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
133 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
134 Liu Y, Zhang Y, Zhao Y, Gao D, Xing J, Liu H. High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer. Oncol Lett. 2016;12:3825-3835. [PMID: 27895737 DOI: 10.3892/ol.2016.5169] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
135 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
136 Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, Batuello CN, Safa AR, Hanenberg H, Territo PR, Sandusky GE, Mayo LD, Eischen CM, Shannon HE, Pollok KE. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther 2015;14:2850-63. [PMID: 26494859 DOI: 10.1158/1535-7163.MCT-15-0237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
137 Bhattacharya S, Asaithamby A. Repurposing DNA repair factors to eradicate tumor cells upon radiotherapy. Transl Cancer Res 2017;6:S822-39. [PMID: 30613483 DOI: 10.21037/tcr.2017.05.22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
138 McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, Ushey K, Sipahimalani P, Bryan J, Rose AM, Hieter P. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 2012;8:e1002574. [PMID: 22412391 DOI: 10.1371/journal.pgen.1002574] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
139 Kim KM, Moon YJ, Park SH, Park HJ, Wang SI, Park HS, Lee H, Kwon KS, Moon WS, Lee DG, Kim JR, Jang KY. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. PLoS One 2016;11:e0163193. [PMID: 27643881 DOI: 10.1371/journal.pone.0163193] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
140 Renna C, Salaroli R, Cocchi C, Cenacchi G. XAV939-mediated ARTD activity inhibition in human MB cell lines. PLoS One 2015;10:e0124149. [PMID: 25835728 DOI: 10.1371/journal.pone.0124149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
141 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
142 Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers (Basel) 2018;10:E514. [PMID: 30558195 DOI: 10.3390/cancers10120514] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 16.3] [Reference Citation Analysis]
143 Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep 2014;6:154-8. [PMID: 25419441 DOI: 10.1007/s12609-014-0152-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
144 Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A. A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. Mol Cancer Ther 2019;18:204-12. [PMID: 30305342 DOI: 10.1158/1535-7163.MCT-18-0243] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
145 Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget 2011;2:259-64. [PMID: 21436470 DOI: 10.18632/oncotarget.244] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
146 Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 2014;9:1-11. [PMID: 24476748 DOI: 10.2147/CE.S52197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
147 Breunig C, Pahl J, Küblbeck M, Miller M, Antonelli D, Erdem N, Wirth C, Will R, Bott A, Cerwenka A, Wiemann S. MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis 2017;8:e2973. [PMID: 28771222 DOI: 10.1038/cddis.2017.364] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
148 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 39] [Article Influence: 15.8] [Reference Citation Analysis]
149 Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 2013;12:2043-54. [PMID: 23873849 DOI: 10.1158/1535-7163.MCT-13-0108] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
150 Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411-424. [PMID: 22713970 DOI: 10.1038/nrm3376] [Cited by in Crossref: 712] [Cited by in F6Publishing: 653] [Article Influence: 79.1] [Reference Citation Analysis]
151 Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med 2018;7:11. [PMID: 29541939 DOI: 10.1186/s40169-018-0185-6] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 44.0] [Reference Citation Analysis]
152 Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour WY. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells. Mol Oncol 2014;8:1616-25. [PMID: 25028150 DOI: 10.1016/j.molonc.2014.06.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
153 Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol 2012;1:85-97. [PMID: 25054302 DOI: 10.2217/cns.12.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
154 Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BK. Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr 2020;4:pkaa002. [PMID: 32211581 DOI: 10.1093/jncics/pkaa002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Mathe A, Scott RJ, Avery-Kiejda KA. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. Int J Mol Sci 2015;16:28347-76. [PMID: 26633365 DOI: 10.3390/ijms161226090] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
156 Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol 2016;37:6143-53. [PMID: 26614429 DOI: 10.1007/s13277-015-4465-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
157 Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res 2017;77:2213-21. [PMID: 28249905 DOI: 10.1158/0008-5472.CAN-16-2717] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 24.8] [Reference Citation Analysis]
158 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
159 Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer 2018;18:1074. [PMID: 30400780 DOI: 10.1186/s12885-018-4979-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
160 Liu M, Ma W, Zhao D, Li J, Li Q, Liu Y, Hao L, Lin Y. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer. ACS Appl Mater Interfaces 2021;13:25825-35. [PMID: 34038071 DOI: 10.1021/acsami.1c07297] [Reference Citation Analysis]
161 Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-9. [PMID: 22157293 DOI: 10.1097/PPO.0b013e318238f579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
162 Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst) 2011;10:1003-13. [PMID: 21840268 DOI: 10.1016/j.dnarep.2011.07.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
163 Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. Breast Cancer Res Treat 2019;177:383-93. [PMID: 31172407 DOI: 10.1007/s10549-019-05305-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
164 Secq V, Villeret J, Fina F, Carmassi M, Carcopino X, Garcia S, Metellus I, Boubli L, Iovanna J, Charpin C. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. Br J Cancer 2014;110:1045-52. [PMID: 24423920 DOI: 10.1038/bjc.2013.794] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
165 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
166 Wu W, Zhu H, Liang Y, Kong Z, Duan X, Li S, Zhao Z, Yang D, Zeng G. Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients. Int Urol Nephrol 2014;46:1345-9. [PMID: 24436031 DOI: 10.1007/s11255-014-0642-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
167 Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol 2021;161:653-9. [PMID: 33736856 DOI: 10.1016/j.ygyno.2021.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 2014;15:e625-34. [PMID: 25456381 DOI: 10.1016/S1470-2045(14)70364-X] [Cited by in Crossref: 111] [Cited by in F6Publishing: 69] [Article Influence: 15.9] [Reference Citation Analysis]
169 Ju J, Zhu AJ, Yuan P. Progress in targeted therapy for breast cancer. Chronic Dis Transl Med 2018;4:164-75. [PMID: 30276363 DOI: 10.1016/j.cdtm.2018.04.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
170 Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H, Errihani H. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health 2012;12:35. [PMID: 23039971 DOI: 10.1186/1472-6874-12-35] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
171 Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3:623-36. [PMID: 21953712 DOI: 10.1002/emmm.201100176] [Cited by in Crossref: 160] [Cited by in F6Publishing: 139] [Article Influence: 16.0] [Reference Citation Analysis]
172 Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012;2012:915375. [PMID: 22619725 DOI: 10.1155/2012/915375] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
173 Xu Y, Ju L, Tong J, Zhou C, Yang J. Supervised Machine Learning Predictive Analytics For Triple-Negative Breast Cancer Death Outcomes. Onco Targets Ther 2019;12:9059-67. [PMID: 31802913 DOI: 10.2147/OTT.S223603] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
174 Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging 2017;44:1420-7. [PMID: 28456837 DOI: 10.1007/s00259-017-3709-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
175 Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther 2015;16:225-32. [PMID: 25648299 DOI: 10.4161/15384047.2014.986973] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
176 Hiller DJ, Chu QD. Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. Int J Breast Cancer 2012;2012:829315. [PMID: 22295252 DOI: 10.1155/2012/829315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
177 Wang Z, Wang F, Tang T, Guo C. The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med 2012;6:156-64. [PMID: 22660976 DOI: 10.1007/s11684-012-0197-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
178 Hyslop T, Michael Y, Avery T, Rui H. Population and target considerations for triple-negative breast cancer clinical trials. Biomark Med 2013;7:11-21. [PMID: 23387481 DOI: 10.2217/bmm.12.114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
179 Jácome AA, Coutinho AK, Lima EM, Andrade AC, Dos Santos JS. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol. 2016;22:1160-1171. [PMID: 26811654 DOI: 10.3748/wjg.v22.i3.1160] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
180 Narrandes S, Huang S, Murphy L, Xu W. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC). BMC Cancer 2018;18:22. [PMID: 29301506 DOI: 10.1186/s12885-017-3939-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
181 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
182 Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med 2014;6:229ra42. [PMID: 24670686 DOI: 10.1126/scitranslmed.3008291] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
183 Hegedűs C, Boros G, Fidrus E, Kis GN, Antal M, Juhász T, Janka EA, Jankó L, Paragh G, Emri G, Bai P, Remenyik É. PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes-Implications for UV-Induced DNA Repair and Photocarcinogenesis. Cancers (Basel) 2019;12:E5. [PMID: 31861350 DOI: 10.3390/cancers12010005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
184 Boac BM, Abbasi F, Ismail-Khan R, Xiong Y, Siddique A, Park H, Han M, Saeed-Vafa D, Soliman H, Henry B, Pena MJ, McClung EC, Robertson SE, Todd SL, Lopez A, Sun W, Apuri S, Lancaster JM, Berglund AE, Magliocco AM, Marchion DC. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep 2019;9:17496. [PMID: 31767884 DOI: 10.1038/s41598-019-53695-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
185 Upreti M, Jyoti A, Johnson SE, Swindell EP, Napier D, Sethi P, Chan R, Feddock JM, Weiss HL, O'Halloran TV, Evers BM. Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. Oncotarget 2016;7:41559-74. [PMID: 27223428 DOI: 10.18632/oncotarget.9490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
186 Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013;10:688-96. [PMID: 24129347 DOI: 10.1038/nrclinonc.2013.177] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
187 Ma W, Halweg CJ, Menendez D, Resnick MA. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A 2012;109:6590-5. [PMID: 22493268 DOI: 10.1073/pnas.1118078109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
188 McMahon KA, Stroud DA, Gambin Y, Tillu V, Bastiani M, Sierecki E, Polinkovsky ME, Hall TE, Gomez GA, Wu Y, Parat MO, Martel N, Lo HP, Khanna KK, Alexandrov K, Daly R, Yap A, Ryan MT, Parton RG. Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response. Elife 2021;10:e61407. [PMID: 34142659 DOI: 10.7554/eLife.61407] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15. [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
190 Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121:8-16. [PMID: 25043972 DOI: 10.1002/cncr.28914] [Cited by in Crossref: 169] [Cited by in F6Publishing: 167] [Article Influence: 24.1] [Reference Citation Analysis]
191 Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer 2018;18:179. [PMID: 29433453 DOI: 10.1186/s12885-018-4098-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
192 Fojo T, Amiri-Kordestani L, Bates SE. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst 2011;103:1738-40. [PMID: 22045362 DOI: 10.1093/jnci/djr386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
193 Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. Cochrane Database Syst Rev 2021;4:CD011395. [PMID: 33886122 DOI: 10.1002/14651858.CD011395.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
194 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. Oncol Lett 2015;9:2825-32. [PMID: 26137155 DOI: 10.3892/ol.2015.3072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
195 Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD. Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. NPJ Breast Cancer 2021;7:29. [PMID: 33753748 DOI: 10.1038/s41523-021-00240-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med. 2011;17:854-862. [PMID: 21424107 DOI: 10.2119/molmed.2010.00240] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
197 Li C, Li X, Li G, Sun L, Zhang W, Jiang J, Ge Q. Identification of a prognosis‑associated signature associated with energy metabolism in triple‑negative breast cancer. Oncol Rep 2020;44:819-37. [PMID: 32582991 DOI: 10.3892/or.2020.7657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
198 Recchia F, Candeloro G, Desideri G, Necozione S, Recchia CO, Cirulli V, Rea S. Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. Cancer Med 2012;1:89-95. [PMID: 23342258 DOI: 10.1002/cam4.3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
199 Ge L, Tang Y, Zhang QN, Tian JH, Wang XH, Pieper D, Pan B, Li L, Ling J, Bing ZT, Yang KH. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget 2017;8:59539-51. [PMID: 28938657 DOI: 10.18632/oncotarget.19102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
200 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
201 Han Y, Lian S, Cui X, Meng K, Győrffy B, Jin T, Huang D. Potential options for managing LOX+ ER- breast cancer patients. Oncotarget 2016;7:32893-901. [PMID: 27147578 DOI: 10.18632/oncotarget.9073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
202 Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. Br J Cancer 2014;111:2051-7. [PMID: 25268370 DOI: 10.1038/bjc.2014.504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
203 Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Traina T, McCormick B, Powell S, Ho AY. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol 2013;20:3469-76. [PMID: 23686101 DOI: 10.1245/s10434-013-3011-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
204 Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Int J Biol Sci 2016;12:1500-10. [PMID: 27994514 DOI: 10.7150/ijbs.16176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
205 Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis. Oncotarget 2016;7:7629-39. [PMID: 26399274 DOI: 10.18632/oncotarget.5367] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
206 Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). J Enzyme Inhib Med Chem 2020;35:1606-15. [PMID: 32779949 DOI: 10.1080/14756366.2020.1804382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
207 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 14.2] [Reference Citation Analysis]
208 Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci USA. 2014;111:14710-14715. [PMID: 25267626 DOI: 10.1073/pnas.1408556111] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 12.6] [Reference Citation Analysis]
209 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
210 Jhan JR, Andrechek ER. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene 2017;36:3553-61. [PMID: 28135251 DOI: 10.1038/onc.2016.503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
211 Morris LG, Chan TA. Therapeutic targeting of tumor suppressor genes. Cancer 2015;121:1357-68. [PMID: 25557041 DOI: 10.1002/cncr.29140] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 9.9] [Reference Citation Analysis]
212 Ang JE, Kaye S, Banerji U. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr Drug Targets 2012;13:1525-34. [PMID: 22974395 DOI: 10.2174/138945012803530062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
213 Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2016;43:1937-44. [PMID: 27129866 DOI: 10.1007/s00259-016-3402-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
214 Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med 2014;7:307-16. [PMID: 25342917 DOI: 10.2147/PGPM.S39765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
215 Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs 2013;15:473-92. [PMID: 23760780 DOI: 10.1007/s40272-013-0037-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
216 Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 2017;9:493-511. [PMID: 28717401 DOI: 10.1177/1758834017711380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
217 Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing Clinical Trials to Streamline Drug Development. Clin Cancer Res 2015;21:4527-35. [PMID: 26473188 DOI: 10.1158/1078-0432.CCR-15-0039] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
218 Zakaria Z, Zulkifle MF, Wan Hasan WAN, Azhari AK, Abdul Raub SH, Eswaran J, Soundararajan M, Syed Husain SNA. Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. Onco Targets Ther 2019;12:7749-56. [PMID: 31571924 DOI: 10.2147/OTT.S214611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
219 Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol 2012;83:741-6. [PMID: 22222428 DOI: 10.1016/j.bcp.2011.12.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
220 Haanpää M, Pylkäs K, Moilanen JS, Winqvist R. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families. BMC Med Genet 2013;14:82. [PMID: 23941127 DOI: 10.1186/1471-2350-14-82] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
221 Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3:257-67. [PMID: 22084640 DOI: 10.1177/1758834011417039] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
222 Turner NC, Tutt AN. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res 2012;14:115. [PMID: 23146216 DOI: 10.1186/bcr3332] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
223 Mun SG, Choi HW, Lee JM, Lim JH, Ha JH, Kang MJ, Kim EJ, Kang L, Chung BG. rGO nanomaterial-mediated cancer targeting and photothermal therapy in a microfluidic co-culture platform. Nano Converg 2020;7:10. [PMID: 32180051 DOI: 10.1186/s40580-020-0220-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
224 Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 2018;29:1763-70. [PMID: 29878040 DOI: 10.1093/annonc/mdy201] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 20.0] [Reference Citation Analysis]
225 Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 2011;17:6973-84. [PMID: 21908578 DOI: 10.1158/1078-0432.CCR-11-0761] [Cited by in Crossref: 70] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
226 Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117-132. [PMID: 23386910 DOI: 10.7150/jca.4925] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
227 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
228 Liu R, Zhi X, Zhou Z, Zhang H, Yang R, Zou T, Chen C. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1. Sci Rep 2018;8:1138. [PMID: 29348684 DOI: 10.1038/s41598-018-19489-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
229 Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012;30:497-506. [PMID: 22231042 DOI: 10.1200/JCO.2011.38.6060] [Cited by in Crossref: 67] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
230 Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 2014;23:567-77. [PMID: 24882351 DOI: 10.1016/j.soc.2014.03.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
231 Tudoran OM, Balacescu O, Berindan-Neagoe I. Breast cancer stem-like cells: clinical implications and therapeutic strategies. Clujul Med 2016;89:193-8. [PMID: 27152067 DOI: 10.15386/cjmed-559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
232 Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30:463-471. [PMID: 21718592 DOI: 10.5732/cjc.011.10111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
233 Abdel-Latif M, Youness RA. Why natural killer cells in triple negative breast cancer? World J Clin Oncol 2020;11:464-76. [PMID: 32821652 DOI: 10.5306/wjco.v11.i7.464] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
234 Williamson SR, Cheng L. Potential for targeted therapy in prostate cancers with ERG abnormalities. Asian J Androl 2011;13:781-2. [PMID: 21785441 DOI: 10.1038/aja.2011.100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2012;134:1149-59. [PMID: 22763464 DOI: 10.1007/s10549-012-2126-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
236 Barnabas N, Cohen D. Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer 2013;2013:872743. [PMID: 23401782 DOI: 10.1155/2013/872743] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
237 Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 2011;10:2320-9. [PMID: 21926192 DOI: 10.1158/1535-7163.MCT-11-0356] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
238 Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model. PLoS One 2016;11:e0149194. [PMID: 26866698 DOI: 10.1371/journal.pone.0149194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
239 Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 2017;8:120-34. [PMID: 28439493 DOI: 10.5306/wjco.v8.i2.120] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 75] [Article Influence: 23.8] [Reference Citation Analysis]
240 Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 2013;9:1799-808. [PMID: 23293085 DOI: 10.1002/smll.201201510] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
241 Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013;2013:137414. [PMID: 23864953 DOI: 10.1155/2013/137414] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 10.6] [Reference Citation Analysis]
242 Parkes EE, Kennedy RD. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. Oncologist 2016;21:586-93. [PMID: 27022037 DOI: 10.1634/theoncologist.2015-0438] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
243 Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 2019;8:F1000 Faculty Rev-1342. [PMID: 31448088 DOI: 10.12688/f1000research.18888.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
244 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 117] [Article Influence: 26.6] [Reference Citation Analysis]
245 Quesada A, O'Valle F, Montoro-Molina S, Gómez-Morales M, Caba-Molina M, González JF, de Gracia MC, Osuna A, Vargas F, Wangensteen R. 5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats. Biosci Rep 2018;38:BSR20171313. [PMID: 29599129 DOI: 10.1042/BSR20171313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Glénisson M, Vacher S, Callens C, Susini A, Cizeron-Clairac G, Le Scodan R, Meseure D, Lerebours F, Spyratos F, Lidereau R, Bièche I. Identification of new candidate therapeutic target genes in triple-negative breast cancer. Genes Cancer 2012;3:63-70. [PMID: 22893791 DOI: 10.1177/1947601912449832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
247 Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 2014;8:145-55. [PMID: 25368521 DOI: 10.4137/BCBCR.S18715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
248 Maugeri-Saccà M, Zeuner A, De Maria R. Therapeutic targeting of cancer stem cells. Front Oncol. 2011;1:10. [PMID: 22655230 DOI: 10.3389/fonc.2011.00010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
249 Mohan A, Ponnusankar S. Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci 2013;75:251-61. [PMID: 24082340 DOI: 10.4103/0250-474X.117396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
250 Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776-82. [PMID: 23047548 DOI: 10.1038/bjc.2012.451] [Cited by in Crossref: 332] [Cited by in F6Publishing: 272] [Article Influence: 36.9] [Reference Citation Analysis]